Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.

BACKGROUND: Although case-control studies have identified numerous single nucleotide polymorphisms (SNPs) associated with prostate cancer, the clinical role of these SNPs remains unclear. OBJECTIVE: Evaluate previously identified SNPs for association with prostate cancer and accuracy in predicting p...

Full description

Bibliographic Details
Main Authors:	Klein, R, Hallden, C, Gupta, A, Savage, C, Dahlin, A, Bjartell, A, Manjer, J, Scardino, P, Ulmert, D, Wallström, P, Vickers, A, Lilja, H
Format:	Journal article
Language:	English
Published:	2012

Similar Items

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
by: Vickers, A, et al.
Published: (2010)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
by: Vickers, A, et al.
Published: (2010)

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
by: Lilja, H, et al.
Published: (2011)

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
by: Vickers, A, et al.
Published: (2011)

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
by: Ulmert, D, et al.
Published: (2008)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
by: Lilja, H, et al.
Published: (2008)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
by: Savage, C, et al.
Published: (2010)

Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
by: Klein, R, et al.
Published: (2010)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
by: Lilja, H, et al.
Published: (2008)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
by: Vickers, A, et al.
Published: (2010)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
by: Ulmert, D, et al.
Published: (2008)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
by: Vickers, A, et al.
Published: (2009)

Five genetic variants associated with prostate cancer.
by: Vickers, A, et al.
Published: (2008)

Tumor markers in prostate cancer I: blood-based markers.
by: Shariat, S, et al.
Published: (2011)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
by: Vickers, A, et al.
Published: (2010)

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
by: Ulmert, D, et al.
Published: (2009)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
by: Vickers, A, et al.
Published: (2009)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
by: Evans-Axelsson, S, et al.
Published: (2012)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
by: Vickers, A, et al.
Published: (2010)

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
by: Vickers, A, et al.
Published: (2007)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
by: Vickers, A, et al.
Published: (2011)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
by: Christensson, A, et al.
Published: (2011)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
by: Cao, Y, et al.
Published: (2002)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
by: Berglund Göran, et al.
Published: (2008-02-01)

Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.
by: O'Brien, M, et al.
Published: (2011)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
by: Siivola, P, et al.
Published: (2000)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
by: Steuber, T, et al.
Published: (2007)

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
by: Ulmert, D, et al.
Published: (2012)

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
by: Lilja, H, et al.
Published: (2007)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.
by: Gupta, A, et al.
Published: (2010)

Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?
by: Vickers, A, et al.
Published: (2010)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
by: Michael Tzeng, et al.
Published: (2021-08-01)

Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels.
by: Xu, X, et al.
Published: (2010)

Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA.
by: Sävblom, C, et al.
Published: (2009)

Prostate cancer polygenic risk score and prediction of lethal prostate cancer
by: Robert J. Klein, et al.
Published: (2022-04-01)

Increase in percent free prostate-specific antigen in men with chronic kidney disease.
by: Bruun, L, et al.
Published: (2009)

Screening for prostate cancer: an update.
by: Shariat, S, et al.
Published: (2008)

Susceptibility loci associated with prostate cancer progression and mortality.
by: Gallagher, D, et al.
Published: (2010)

Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
by: Dahlman, A, et al.
Published: (2010)

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
by: Vickers, A, et al.
Published: (2010)